Welcome to our dedicated page for Rapt Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on Rapt Therapeutics stock.
RAPT Therapeutics, Inc. (RAPT) is a clinical-stage biopharmaceutical leader developing oral therapies for oncology and inflammatory diseases. This news hub provides investors and industry professionals with verified updates on the company's scientific advancements and corporate developments.
Comprehensive Resource: Track all official announcements including clinical trial milestones, regulatory submissions, financial results, and strategic partnerships. Our curated collection ensures efficient access to material developments affecting RAPT's position in immunology-focused drug discovery.
Key Coverage Areas: Stay informed about CCR4-targeting therapies like tivumecirnon (FLX475) and inflammatory disease candidates such as zelnecirnon (RPT193). Receive updates on FDA communications, research collaborations, and pipeline expansion efforts without speculative commentary.
Strategic Monitoring: Bookmark this page for real-time access to primary source materials. Professionals relying on precision medicine updates will find this centralized repository essential for tracking RAPT's progress in addressing unmet medical needs through innovative immunology approaches.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage biopharmaceutical company, announced that President and CEO Brian Wong, M.D., Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference. The event will take place on January 11, 2022, at 9:00 a.m. ET. RAPT focuses on developing oral small molecule therapies for inflammatory diseases and oncology. The company has advanced drug candidates RPT193 and FLX475, targeting CCR4 for treating inflammation and cancer. Access the presentation via the RAPT website.
RAPT Therapeutics reported a net loss of $18.7 million for Q3 2021, up from $14.6 million in Q3 2020. Research and development expenses rose to $15.7 million due to clinical trial costs for FLX475 and RPT193. Total net loss for the nine months ended September 30, 2021, was $51.3 million, compared to $40.2 million in the prior year. RAPT aims to advance RPT193 into Phase 2 trials in 2022 and is focusing on FLX475 for various cancers, with data updates expected at a medical meeting in 2022. The company holds $210.8 million in cash and securities.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, has appointed Lori Lyons-Williams to its Board of Directors. With over 20 years of experience, she previously held key roles at Neumora Therapeutics and Dermira, driving strategic success in biotechnology. Her expertise is expected to significantly benefit RAPT's inflammation and oncology product pipeline, particularly RPT193. RAPT develops oral small molecule therapies for patients with severe unmet needs, focusing on inflammatory diseases and cancer.
RAPT Therapeutics, based in South San Francisco, announced that CEO Brian Wong will present at key investor conferences in November 2021. These include the Stifel 2021 Virtual Healthcare Conference on November 15 at 2:00 p.m. ET and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22 available on-demand at 10:00 a.m. ET. RAPT Therapeutics focuses on developing oral small molecule therapies for inflammatory diseases and oncology, with drug candidates like RPT193 and FLX475 targeting CCR4.
RAPT Therapeutics, Inc. (Nasdaq: RAPT) announced the presentation of clinical efficacy data from its Phase 1b trial of RPT193, an oral CCR4 inhibitor for moderate-to-severe atopic dermatitis. The presentation will occur at the 4th Inflammatory Skin Disease Summit in New York, from November 3-6, 2021. The trial is designed to demonstrate the efficacy of RPT193 compared to a placebo. This is part of RAPT's commitment to developing therapies for significant unmet needs in oncology and inflammatory diseases.
RAPT Therapeutics announced positive topline results from its Phase 1b clinical trial of RPT193 for moderate-to-severe atopic dermatitis, presented at the EADV Congress. The trial demonstrated significant efficacy across key exploratory endpoints including EASI and vIGA, with benefits observed persisting two weeks post-treatment. RPT193 was well tolerated, showing a clean safety profile with no serious adverse events. The company plans to advance RPT193 to a Phase 2b trial in atopic dermatitis and a Phase 2a trial in asthma, highlighting its potential in treating inflammatory diseases.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Brian Wong will present at the 2021 Cantor Virtual Healthcare Conference on September 27, 2021, at 2:00 p.m. EST. The company focuses on developing oral small molecule therapies for unmet needs in oncology and inflammatory diseases, with two drug candidates, FLX475 and RPT193, targeting CCR4 receptors. For access to the live webcast and archived recordings, visit the RAPT Therapeutics website.
RAPT Therapeutics announced it will present clinical safety and efficacy data for RPT193, an oral CCR4 inhibitor, from its Phase 1b trial targeting moderate-to-severe atopic dermatitis at the upcoming 30th European Academy of Dermatology and Venereology Congress on September 30, 2021. The presentation highlights a significant step in RAPT's ongoing commitment to develop novel therapies for unmet needs in oncology and inflammatory diseases.
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2021 – RAPT Therapeutics (Nasdaq: RAPT) announced that Brian Wong, M.D., Ph.D., President and CEO, will present at key investor conferences in September. Notably, he will speak at the Wells Fargo 2021 Virtual Healthcare Conference on September 9 at 8:00 a.m. EST and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 a.m. EST. For live webcasts and archived recordings, visit RAPT's official website. RAPT focuses on oral therapies for oncology and inflammatory diseases, advancing drug candidates targeting CCR4.
RAPT Therapeutics reported Q2 2021 financial results, highlighting a net loss of $16.1 million, up from $12.4 million year-over-year. R&D expenses rose to $13.2 million, driven by clinical trial costs for FLX475. The company successfully completed a public offering, generating $134.6 million, enhancing its cash position to $223.3 million. Notable achievements include positive topline results from the Phase 1b trial of RPT193 for atopic dermatitis. RAPT remains optimistic about advancing its drug development initiatives in oncology and inflammatory diseases.
